MediWound (NASDAQ:MDWD) Price Target Lowered to $25.00 at HC Wainwright

MediWound (NASDAQ:MDWD) had its price target decreased by HC Wainwright from $28.00 to $25.00 in a report published on Wednesday,Benzinga reports. HC Wainwright currently has a buy rating on the biopharmaceutical company’s stock.

Separately, StockNews.com raised MediWound to a “sell” rating in a research report on Monday, August 5th.

MediWound Trading Up 3.3 %

Shares of MDWD opened at $17.45 on Wednesday. The company has a market cap of $188.29 million, a price-to-earnings ratio of -8.08 and a beta of 0.83. The business’s fifty day simple moving average is $17.16 and its two-hundred day simple moving average is $17.38. MediWound has a 12 month low of $8.48 and a 12 month high of $24.00.

Institutional Investors Weigh In On MediWound

A number of hedge funds have recently added to or reduced their stakes in MDWD. Barclays PLC grew its holdings in shares of MediWound by 311.3% in the third quarter. Barclays PLC now owns 11,163 shares of the biopharmaceutical company’s stock worth $202,000 after acquiring an additional 8,449 shares during the period. State Street Corp increased its position in shares of MediWound by 219.6% during the 3rd quarter. State Street Corp now owns 66,258 shares of the biopharmaceutical company’s stock valued at $1,197,000 after purchasing an additional 45,529 shares during the last quarter. Point72 Asset Management L.P. bought a new position in shares of MediWound in the 3rd quarter worth approximately $212,000. Investor AB purchased a new position in shares of MediWound in the third quarter worth approximately $15,750,000. Finally, MetLife Investment Management LLC bought a new stake in MediWound during the third quarter valued at approximately $89,000. 46.83% of the stock is currently owned by hedge funds and other institutional investors.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.